Overview
Thrombophlebitis of the mesenteric vein involves inflammation and thrombosis within the mesenteric venous system, often complicating conditions like portal hypertension or malignancy, leading to significant abdominal pain, bowel ischemia, and potentially life-threatening complications such as bowel infarction 123.Diagnosis
Clinical presentation includes severe abdominal pain, nausea, vomiting, and signs of systemic inflammatory response 123.
Imaging studies (CT, MRI) are crucial for visualizing thrombosis and assessing bowel viability 123.
Laboratory tests may show elevated inflammatory markers and coagulation abnormalities 123.
Endoscopy or angiography can confirm the diagnosis and assess the extent of involvement 123.Management
First-line treatment: Anticoagulation therapy, often with heparin initially followed by transition to oral anticoagulants like warfarin or direct oral anticoagulants (DOACs) such as dabigatran 123.
Adjunctive treatments: Supportive care including fluid resuscitation, pain management, and nutritional support 123.
Management of bleeding complications: Careful monitoring and management of bleeding risks, possibly involving blood transfusions and dose adjustments of anticoagulants 12.Special Populations
Elderly: Increased risk of bleeding complications; careful monitoring of renal function and concomitant medications is essential 13.
Comorbidities: Patients with concurrent use of interacting medications (e.g., aspirin, NSAIDs) require vigilant management to avoid supratherapeutic INR levels and bleeding 23.Key Recommendations
Initiate anticoagulation therapy promptly with heparin followed by transition to oral anticoagulants based on patient-specific factors and risk assessment (Evidence: Moderate 13).
Closely monitor for bleeding complications, especially in elderly patients and those with renal impairment, adjusting anticoagulant doses accordingly (Evidence: Moderate 13).
Avoid concomitant use of potent platelet inhibitors and NSAIDs to minimize bleeding risk; monitor INR closely in patients on warfarin (Evidence: Moderate 23).References
1 Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L et al.. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013. link
2 Gschwind L, Rollason V, Lovis C, Boehlen F, Bonnabry P, Dayer P et al.. Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital. European journal of clinical pharmacology 2013. link
3 Verhovsek M, Motlagh B, Crowther MA, Kennedy C, Dolovich L, Campbell G et al.. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC geriatrics 2008. link